A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).

MLA

Matsubara, Nobuaki, et al. “A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-Resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study).” Japanese Journal of Clinical Oncology, vol. 44, no. 12, Dec. 2014, pp. 1216–26. EBSCOhost, https://doi.org/10.1093/jjco/hyu149.

APA

Matsubara, N., Uemura, H., Satoh, T., Suzuki, H., Nishiyama, T., Uemura, H., Hashine, K., Imanaka, K., Ozono, S., & Akaza, H. (2014). A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Japanese Journal of Clinical Oncology, 44(12), 1216–1226. https://doi.org/10.1093/jjco/hyu149

Chicago

Matsubara, Nobuaki, Hirotsugu Uemura, Takefumi Satoh, Hiroyoshi Suzuki, Tsutomu Nishiyama, Hiroji Uemura, Katsuyoshi Hashine, Keiichiro Imanaka, Seiichiro Ozono, and Hideyuki Akaza. 2014. “A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-Resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study).” Japanese Journal of Clinical Oncology 44 (12): 1216–26. doi:10.1093/jjco/hyu149.